干癣性关节炎市场 - KOL的考察

本报告提供干癣性关节炎市场相关调查分析，对已上市的治疗方法和开发平台有的治疗方法的KOL的考察。

目录

摘要整理

干癣性关节炎的现在与未来的治疗流程

调查目的

已通过核准的医药品

• 抗肿瘤坏死因子剂
  • 重要考虑因素摘要
• Interleukin-17 抑制剂
  • Cosentyx（苏金单抗；诺华）
  • Taltz（ixekizumab；礼来公司）
• 白血球介素 12/23、白血球介素 23 抑制剂
  • Stelara（优特克单抗；Janssen）
  • Tremfya（guselkumab；杨森）
  • Skyrizi（risankizumab；艾伯维/勃林格殷格翰）
• Janus 激? (JAK) 抑制剂
  • Xeljanz（託法替尼；辉瑞）
  • Rinvoq（upadacitinib；艾伯维）
• 4型环核?酸磷酸二酯?抑制剂
  • Otezla（阿普斯特；安进）
• T细胞活化抑制剂
  • Orencia（阿巴西普；百时美施贵宝）

在研药物

• Interleukin-17 抑制剂
  • Bimzelx（bimekizumab；UCB）
  • Izokibep（Affibody/Acelyrin）
  • Sonelokimab（MoonLake 免疫疗法）
• Interleukin-23 抑制剂
  • Ilumya/Ilumetri（tildrakizumab；Almirall/Sun Pharmaceutical）
• 酪胺酸激? 2 (TYK2) 抑制剂
  • Sotyktu（deucravacitinib；百时美施贵宝）
  • TAK-279（武田）
• TYK2/JAK-1 抑制剂
  • Brepocitinib（Priovant Therapeutics）
• 丝裂原激活蛋白激?活化蛋白激? 2 抑制剂
  • Zunsemetinib（Aclaris Therapeutics）

干癣关节炎治疗的未来趋势与机会

附录

新闻

What clinical and commercial factors are influencing KOLs' prescribing decisions for Novartis' Cosentyx and Lilly's Taltz anti-IL-17 therapies? In the IL-23 inhibitor sector, how do rheumatologists assess the clinical advantages of Janssen's Tremfya and AbbVie/Boehringer Ingelheim's Skyrizi in patients with severe skin disease who have milder arthritis or IBD? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

• 15 Jun 23 KOL Bulletin -- Views on the long-term Phase III data for UCB'S Bimzelx

• 16 Jun 23 KOL Bulletin -- Views on post-hoc analysis of Phase III COSMOS data for Janssen's Tremfya

Table of Contents

Executive summary

Current and future treatment algorithm for psoriatic arthritis

Research objectives

Approved drugs

• Anti-tumour necrosis factor agents
  • Key insights summary
• Interleukin-17 inhibitors
  • Cosentyx (secukinumab; Novartis)
  • Taltz (ixekizumab; Lilly)
• Interleukin-12/23 and interleukin-23 inhibitors
  • Stelara (ustekinumab; Janssen)
  • Tremfya (guselkumab; Janssen)
  • Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
• Janus kinase (JAK) inhibitors
  • Xeljanz (tofacitinib; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
• Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Otezla (apremilast; Amgen)
• T-cell activation inhibitors
  • Orencia (abatacept; Bristol Myers Squibb)

Pipeline drugs

• Interleukin-17 inhibitors
  • Bimzelx (bimekizumab; UCB)
  • Izokibep (Affibody/Acelyrin)
  • Sonelokimab (MoonLake Immunotherapeutics)
• Interleukin-23 inhibitors
  • Ilumya/Ilumetri (tildrakizumab; Almirall/Sun Pharmaceutical)
• Tyrosine kinase 2 (TYK2) inhibitors
  • Sotyktu (deucravacitinib; Bristol Myers Squibb)
  • TAK-279 (Takeda)
• TYK2/JAK-1 inhibitor
  • Brepocitinib (Priovant Therapeutics)
• Mitogen-activated protein kinase-activated protein kinase-2 inhibitor
  • Zunsemetinib (Aclaris Therapeutics)

Future trends and opportunities in psoriatic arthritis treatment

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

News